Founded in June 2002, Liaoning ChengdDa Biotechnology Co., Ltd. (CDBIO) is jointly owned by Liaoning ChengDa Co., Ltd. and Liaoning Provincial Bio-medical Science Engineering Institute. The total investment on the project was about USD20 million.

Our company has adopted the advanced technology of high density microcarriers in bioreactors from BARI consultant in the USA to produce vero cell rabies vaccines for human use and inactivated purified Japanese encephalitis vaccines.

Located in Hunnan New District of Shenyang City, CDBIO has a production capability of 15,000,000 doses of rabies vaccines for human use and a production capability of 20,000,000 doses of inactivated purified Japanese encephalitis vaccines annually. Since 2005, CDBIO has passed the GMP validation issued by SFDA and began to sell rabies vaccine in China from Jan 2006 to Sep 2006, CDBIO sold about 8 million doses rabies vaccine in China, and began to export rabies vaccine to Uzbekistan, Ghana, Belgium. Dr. Neol Miranda, representative of WHO in Asia, has visited CDBIO in May, 2005, and has given good evaluation on the manufacture of CDBIO. There are over 240 employees in CDBIO, 120 of them holding bachelor's degrees, 8 of them holding master's degrees and 1 of them holding doctor's degrees.

CDBIO has continued research on many kinds of vaccines on the basis of bioreactor technology. The sample of Japanese encephalitis vaccine has finished the clinical trials in 2005 and we will start to sell this vaccine in 2007. Rabies vaccines for veterinary use will be produced in 2007. Furthermore, CDBIO will produce influenza vaccines, polio vaccines and several other vaccines in recent years.